Wei Liu1, Zhongxing Liao2, Steven E Schild3, Zhong Liu4, Heng Li5, Yupeng Li6, Peter C Park7, Xiaoqiang Li5, Joshua Stoker3, Jiajian Shen3, Sameer Keole3, Aman Anand3, Mirek Fatyga3, Lei Dong8, Narayan Sahoo5, Sujay Vora3, William Wong3, X Ronald Zhu5, Martin Bues3, Radhe Mohan5. 1. Department of Radiation Oncology, Mayo Clinic Arizona, Phoenix, Arizona; Department of Radiation Physics, University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: Liu.Wei@mayo.edu. 2. Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas. 3. Department of Radiation Oncology, Mayo Clinic Arizona, Phoenix, Arizona. 4. School of Business Administration, Southwestern University of Finance and Economics, Chengdu, Sichuan, China. 5. Department of Radiation Physics, University of Texas MD Anderson Cancer Center, Houston, Texas. 6. Varian Medical Systems, Inc, Palo Alto, California. 7. Department of Radiation Oncology, Emory University, Atlanta, Georgia. 8. Scripps Proton Center, San Diego, California.
Abstract
PURPOSE: We compared conventionally optimized intensity modulated proton therapy (IMPT) treatment plans against worst-case scenario optimized treatment plans for lung cancer. The comparison of the 2 IMPT optimization strategies focused on the resulting plans' ability to retain dose objectives under the influence of patient setup, inherent proton range uncertainty, and dose perturbation caused by respiratory motion. METHODS AND MATERIALS: For each of the 9 lung cancer cases, 2 treatment plans were created that accounted for treatment uncertainties in 2 different ways. The first used the conventional method: delivery of prescribed dose to the planning target volume that is geometrically expanded from the internal target volume (ITV). The second used a worst-case scenario optimization scheme that addressed setup and range uncertainties through beamlet optimization. The plan optimality and plan robustness were calculated and compared. Furthermore, the effects on dose distributions of changes in patient anatomy attributable to respiratory motion were investigated for both strategies by comparing the corresponding plan evaluation metrics at the end-inspiration and end-expiration phase and absolute differences between these phases. The mean plan evaluation metrics of the 2 groups were compared with 2-sided paired Student t tests. RESULTS: Without respiratory motion considered, we affirmed that worst-case scenario optimization is superior to planning target volume-based conventional optimization in terms of plan robustness and optimality. With respiratory motion considered, worst-case scenario optimization still achieved more robust dose distributions to respiratory motion for targets and comparable or even better plan optimality (D95% ITV, 96.6% vs 96.1% [P = .26]; D5%- D95% ITV, 10.0% vs 12.3% [P = .082]; D1% spinal cord, 31.8% vs 36.5% [P = .035]). CONCLUSIONS: Worst-case scenario optimization led to superior solutions for lung IMPT. Despite the fact that worst-case scenario optimization did not explicitly account for respiratory motion, it produced motion-resistant treatment plans. However, further research is needed to incorporate respiratory motion into IMPT robust optimization.
PURPOSE: We compared conventionally optimized intensity modulated proton therapy (IMPT) treatment plans against worst-case scenario optimized treatment plans for lung cancer. The comparison of the 2 IMPT optimization strategies focused on the resulting plans' ability to retain dose objectives under the influence of patient setup, inherent proton range uncertainty, and dose perturbation caused by respiratory motion. METHODS AND MATERIALS: For each of the 9 lung cancer cases, 2 treatment plans were created that accounted for treatment uncertainties in 2 different ways. The first used the conventional method: delivery of prescribed dose to the planning target volume that is geometrically expanded from the internal target volume (ITV). The second used a worst-case scenario optimization scheme that addressed setup and range uncertainties through beamlet optimization. The plan optimality and plan robustness were calculated and compared. Furthermore, the effects on dose distributions of changes in patient anatomy attributable to respiratory motion were investigated for both strategies by comparing the corresponding plan evaluation metrics at the end-inspiration and end-expiration phase and absolute differences between these phases. The mean plan evaluation metrics of the 2 groups were compared with 2-sided paired Student t tests. RESULTS: Without respiratory motion considered, we affirmed that worst-case scenario optimization is superior to planning target volume-based conventional optimization in terms of plan robustness and optimality. With respiratory motion considered, worst-case scenario optimization still achieved more robust dose distributions to respiratory motion for targets and comparable or even better plan optimality (D95% ITV, 96.6% vs 96.1% [P = .26]; D5%- D95% ITV, 10.0% vs 12.3% [P = .082]; D1% spinal cord, 31.8% vs 36.5% [P = .035]). CONCLUSIONS: Worst-case scenario optimization led to superior solutions for lung IMPT. Despite the fact that worst-case scenario optimization did not explicitly account for respiratory motion, it produced motion-resistant treatment plans. However, further research is needed to incorporate respiratory motion into IMPT robust optimization.
Authors: Peter C Park; X Ronald Zhu; Andrew K Lee; Narayan Sahoo; Adam D Melancon; Lifei Zhang; Lei Dong Journal: Int J Radiat Oncol Biol Phys Date: 2011-06-22 Impact factor: 7.038
Authors: Wei Chen; Jan Unkelbach; Alexei Trofimov; Thomas Madden; Hanne Kooy; Thomas Bortfeld; David Craft Journal: Phys Med Biol Date: 2012-01-06 Impact factor: 3.609
Authors: Ming Yang; X Ronald Zhu; Peter C Park; Uwe Titt; Radhe Mohan; Gary Virshup; James E Clayton; Lei Dong Journal: Phys Med Biol Date: 2012-06-07 Impact factor: 3.609
Authors: Martin Stuschke; Andreas Kaiser; Christoph Pöttgen; Wolfgang Lübcke; Jonathan Farr Journal: Radiother Oncol Date: 2012-05-03 Impact factor: 6.280
Authors: Wei Liu; Steven E Schild; Joe Y Chang; Zhongxing Liao; Yu-Hui Chang; Zhifei Wen; Jiajian Shen; Joshua B Stoker; Xiaoning Ding; Yanle Hu; Narayan Sahoo; Michael G Herman; Carlos Vargas; Sameer Keole; William Wong; Martin Bues Journal: Int J Radiat Oncol Biol Phys Date: 2015-11-10 Impact factor: 7.038
Authors: Chenbin Liu; Steven E Schild; Joe Y Chang; Zhongxing Liao; Shawn Korte; Jiajian Shen; Xiaoning Ding; Yanle Hu; Yixiu Kang; Sameer R Keole; Terence T Sio; William W Wong; Narayan Sahoo; Martin Bues; Wei Liu Journal: Int J Radiat Oncol Biol Phys Date: 2018-02-14 Impact factor: 7.038
Authors: Jie Shan; Yunze Yang; Steven E Schild; Thomas B Daniels; William W Wong; Mirek Fatyga; Martin Bues; Terence T Sio; Wei Liu Journal: Med Phys Date: 2020-10-13 Impact factor: 4.071
Authors: Wei Liu; Samir H Patel; Jiajian Jason Shen; Yanle Hu; Daniel P Harrington; Xiaoning Ding; Michele Y Halyard; Steven E Schild; William W Wong; Gary A Ezzell; Martin Bues Journal: Pract Radiat Oncol Date: 2016-02-13
Authors: Yu An; Jie Shan; Samir H Patel; William Wong; Steven E Schild; Xiaoning Ding; Martin Bues; Wei Liu Journal: Med Phys Date: 2017-10-26 Impact factor: 4.071